CYP19A1 and Other metabolic disease: Macromolecular target prediction using the SwissTargetPrediction indicated that these molecules could also target enzymes associated with metabolic diseases (HSD11B1), could be aromatase inhibitors (CYP19A1), and exhibited anti-hepatitis and antihyperthyroidism (SHBG) activities, among others (Figure 9).